Form 4: Cytokinetics Director Wysenski Acquires Shares

Cytokinetics Director Nancy Wysenski acquired 98 shares of common stock at $63.44 per share, increasing her direct beneficial ownership to 30,971 shares.

Summary

• Nancy Wysenski, a Director of Cytokinetics Inc. (CYTK), acquired 98 shares of common stock.
• The transaction occurred on January 15, 2026, with shares priced at $63.44 each.
• The shares were received as fully vested common stock in lieu of a cash retainer, pursuant to an Equity in Lieu of Cash Retainer Option available to Board members.
• Following this transaction, Ms. Wysenski directly beneficially owns 30,971 shares of Cytokinetics common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: Slightly positive. While a routine compensation-related transaction, it represents an increase in a director's direct ownership, which can be viewed favorably as it aligns their interests with shareholders.

Positives

• A director increasing their stake in the company, even through compensation, can signal confidence in the company's future prospects.
• The transaction aligns the director's financial interests more closely with those of other shareholders.

Future Outlook

This filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider transactions, such as this director's acquisition of shares, are common in the biotechnology and pharmaceutical industries, often reflecting compensation structures that include equity components to align management and board interests with shareholder value.

Related Party Transactions

• The acquisition of shares in lieu of a cash retainer is a form of compensation provided by the company to a director, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased insider ownership can be seen as a positive signal, potentially fostering greater confidence in the company's leadership and future direction.

Key Dates

Keywords

CYTK, Cytokinetics, Form 4, Insider Transaction, Director Stock Acquisition, Beneficial Ownership, Equity Compensation, Rule 10b5-1